FilingReader Intelligence

Maccura gains IVDR certification, extends key shareholder agreement

March 31, 2025 at 12:46 PM UTCBy FilingReader AI

Maccura Biotechnology (SZSE:300463) announced it has received IVDR CE certification from BSI for four in-vitro diagnostic reagent products. These certifications, effective from March 19, 2025, through March 27, 2029, cover reagent kits for detecting IgG and IgM antibodies related to Cytomegalovirus and Rubella virus, supporting the diagnosis of infections. The company stated these certifications allow access to the European market. In related news, Maccura also announced the extension of its key shareholder agreement among shareholders Tang Yong, Wang Dengming, and Liu Qilin. Effective March 27, 2025, the extension prolongs the agreement for an additional three years, until March 2028, maintaining their collective control of the company. As of the announcement, these shareholders collectively hold 146,724,156 shares, representing approximately 24.11% of Maccura’s total share capital. The company noted the extension ensures management stability and continued strategic direction.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:300463Shenzhen Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Maccura Biotechnology publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →